Clopidogrel TAD

RSS

clopidogrel

Authorised
This medicine is authorised for use in the European Union.

Overview

This is a summary of the European public assessment report (EPAR) for Clopidogrel TAD. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Clopidogrel TAD.

For practical information about using Clopidogrel TAD, patients should read the package leaflet or contact their doctor or pharmacist.

This EPAR was last updated on 15/05/2018

Authorisation details

Product details
Name
Clopidogrel TAD
Agency product number
EMEA/H/C/001136
Active substance
clopidogrel hydrochloride
International non-proprietary name (INN) or common name
clopidogrel
Therapeutic area (MeSH)
  • Peripheral Vascular Diseases
  • Stroke
  • Myocardial Infarction
Anatomical therapeutic chemical (ATC) code
B01AC06
Generic

This is a generic medicine, which is developed to be the same as a medicine that has already been authorised, called the reference medicine. A generic medicine contains the same active substance(s) as the reference medicine, and is used at the same dose(s) to treat the same disease(s). For more information, see Generic and hybrid medicines.

Publication details
Marketing-authorisation holder
Tad Pharma GmbH
Revision
8
Date of issue of marketing authorisation valid throughout the European Union
23/09/2009
Contact address
TAD Pharma GmbH
Heinz-Lohmann-Strasse 5
D-27472 Cuxhaven
Germany

Product information

10/05/2018 Clopidogrel TAD - EMEA/H/C/001136 - IB/0030

Contents

Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.

Pharmacotherapeutic group

Antithrombotic agents

Therapeutic indication

Clopidogrel is indicated in adults for the prevention of atherothrombotic events in:

    Patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease.

Assessment history

How useful was this page?

Add your rating